Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107276 · ClinicalTrials.gov registry record · Phase 2
S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00107276 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 112 participants.
The verdict
NCT00107276, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one chemotherapy drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cyclophosphamide together with capecitabine works in treating women with stage IV breast cancer.
Interventions
- DRUG cyclophosphamide
- DRUG capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2005-08 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107276
The ClinicalTrials.gov registry entry for NCT00107276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT00107276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00107276 about?
NCT00107276 is a clinical study titled "S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one chemotherapy drug may kill more tumor cells. PURPOSE: This phase II trial i...
What is the current status of trial NCT00107276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2005-08. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00107276?
The interventions under investigation include: cyclophosphamide (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00107276?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.